Evidence map›Paper›PMID 31980029›Full record

ArticleCell communication and signaling : CCS2020

Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.

Hannes Neuwirt, Jan Bouchal, Gvantsa Kharaishvili, Christian Ploner, Karin Jöhrer, Florian Pitterl, Anja Weber, Helmut Klocker, Iris E Eder

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 103 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Deletions ofBiomolecules · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Hannes NeuwirtDepartment of Internal Medicine IV - Nephrology and Hypertension, Medical University of Innsbruck, Innsbruck, Austria.
Jan BouchalDepartment of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic.
Gvantsa KharaishviliDepartment of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic.
Christian PlonerDepartment of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Karin JöhrerTyrolean Cancer Research Institute, Innsbruck, Austria.
Florian PitterlInstitute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Anja WeberDepartment of Urology, Division of Experimental Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
Helmut KlockerDepartment of Urology, Division of Experimental Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
Iris E EderDepartment of Urology, Division of Experimental Urology, Medical University of Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. iris.eder@i-med.ac.at.ORCID 0000-0003-3716-0027
Innsbruck Medical University · ATUniversity Hospital Olomouc · CZTyrolean Cancer Research Institute · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAndrogen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clinical management of patients, also because the molecular mechanisms behind therapy resistance are not yet fully understood. In the present study, we therefore aimed to identify novel targets to intervene with therapy resistance using gene expression analysis of PCa co-culture spheroids where PCa cells are grown in the presence of cancer-associated fibroblasts (CAFs) and which have been previously shown to be a reliable model for antiandrogen resistance.

methodsGene expression changes of co-culture spheroids (LNCaP and DuCaP seeded together with CAFs) were identified by Illumina microarray profiling. Real-time PCR, Western blotting, immunohistochemistry and cell viability assays in 2D and 3D culture were performed to validate the expression of selected targets in vitro and in vivo. Cytokine profiling was conducted to analyze CAF-conditioned medium.

resultsGene expression analysis of co-culture spheroids revealed that CAFs induced a significant upregulation of cholesterol and steroid biosynthesis pathways in PCa cells. Cytokine profiling revealed high amounts of pro-inflammatory, pro-migratory and pro-angiogenic factors in the CAF supernatant. In particular, two genes, 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (HMGCS2) and aldo-keto reductase family 1 member C3 (AKR1C3), were significantly upregulated in PCa cells upon co-culture with CAFs. Both enzymes were also significantly increased in human PCa compared to benign tissue with AKR1C3 expression even being associated with Gleason score and metastatic status. Inhibiting HMGCS2 and AKR1C3 resulted in significant growth retardation of co-culture spheroids as well as of various castration and enzalutamide resistant cell lines in 2D and 3D culture, underscoring their putative role in PCa. Importantly, dual targeting of cholesterol and steroid biosynthesis with simvastatin, a commonly prescribed cholesterol synthesis inhibitor, and an inhibitor against AKR1C3 had the strongest growth inhibitory effect.

conclusionsFrom our results we conclude that CAFs induce an upregulation of cholesterol and steroid biosynthesis in PCa cells, driving them into AR targeted therapy resistance. Blocking both pathways with simvastatin and an AKR1C3 inhibitor may therefore be a promising approach to overcome resistances to AR targeted therapies in PCa. Video abstract.

Indexed as

Disease ProgressionUp-RegulationAgedBenzamidesBiosynthetic PathwaysCancer-Associated FibroblastsCell CycleCell Line, TumorCell ProliferationCell SurvivalCholesterolCulture Media, ConditionedDrug Resistance, NeoplasmExtracellular MatrixGene Expression ProfilingGene Expression Regulation, NeoplasticAR protein, humanBenzamidesCholesterolCulture Media, ConditionedenzalutamideNitrilesPhenylthiohydantoinReceptors, AndrogenSimvastatinAKR1C3AntiandrogensCastration resistanceCholesterolHMGCS2Prostate cancerSimvastatinSteroid metabolism

Identifiers

PMID31980029
PMCPMC6979368
OpenAlexW3005948316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.